Biweekly Docetaxel and Vinorelbine as First-Line Chemotherapy in Metastatic Breast Cancer

Mayordomo, J. I.; Millà, A.; Morales, Serafín; Yubero, A.; Lorenzo, Antonio; Baena, José Manuel; Modolell, A.; Sanz, Javier; Illarramendi, José Juan; García, Maria José; Machengs, I.; Burillo, M.; Trés, A.

doi:10.3816/cbc.2004.n.017

Cited by 15 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, literature data have reported interesting results, probably because of a synergistic effect, when using the 2 drugs in combination. [22][23][24][25][26][27][28][29][30][31][32] The efficacy results observed in the present study are in line with those of previous experiences with the same regimen as reported in Table 4. [22][23][24][25][26][27][28][29][30][31][32] Our data report a 51% ORR with a 17% CR rate and a median survival of 14 months in a series of patients with visceral metastases and heavily pretreated once again confirming the value of the combination of DCT and VNR in the treatment of MBC.…”

Section: Discussionsupporting

confidence: 95%

“…Finally, noteworthy is that no toxic deaths have been recorded. These data are definitely more favorable as compared with those of other experiences, [22][23][24][25][26][27][28][29][30][31][32] particularly with respect to the study by Kornek et al 23 that reported an high incidence of peripheral neurotoxicity (42%) and hematological toxicity with septic complications notwithstanding the use of G-CSF. It is very likely Treating Metastatic Breast Cancer that the differences in safety profile are ascribable to the different treatment schedule since we delivered VNR only on day 1 of each cycle, instead of days 1 and 8 as reported in other experiences.…”

Section: Discussionmentioning

confidence: 42%

See 1 more Smart Citation

Treatment of Metastatic Breast Cancer With Vinorelbine and Docetaxel

Savio¹,

Laudani²,

Leonardi³

et al. 2006

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 95%

Section: Discussionmentioning

confidence: 42%

Treatment of Metastatic Breast Cancer With Vinorelbine and Docetaxel

Savio¹,

Laudani²,

Leonardi³

et al. 2006

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Our results are comparable with findings from other publications of phase II clinical trials where other chemotherapeutic regimens were used as first-line therapy in MBC [31,32,33]. …”

Section: Discussionsupporting

confidence: 83%

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

Shamseddine

Otrock²,

Khalifeh³

et al. 2006

Oncology

View full text Add to dashboard Cite

Background: We tested a sequential combination regimen using cisplatin and vinorelbine (PVn) followed by docetaxel as first-line chemotherapy in a phase II clinical trial in metastatic breast cancer (MBC). Patients and Methods: Thirty-five patients were enrolled. Cisplatin 80 mg/m² was given on day 1 and vinorelbine 30 mg/m² on days 1 and 8 every 3 weeks for 4 cycles. Responding patients received docetaxel 75 mg/m² every 21 days for a maximum of 4 cycles. Three patients were excluded from analysis because of death unrelated to treatment. Results: After a median follow-up of 14 months, 32 patients completed the study. The overall response rate was 53.1%. Complete remission was seen in 5 patients (15.6%), partial response in 12 (37.5%), stable disease in 6 (18.75%), and progressive disease in 9 patients (28.1%). Median time to disease progression was 8 months (range 1–24). At 24 months, 12 (37.5%) patients were alive. A total of 183 cycles were administered. Febrile neutropenia was observed in 4 patients (2.2%). Grade II nephrotoxicity occurred in 12 cycles (6.5%) and grade III vomiting in 31/183 cycles (16.9%). Discussion: PVn is a feasible non-anthracycline option as first-line chemotherapy in patients with metastatic breast cancer and has acceptable toxicity. The sequential addition of 4 cycles of docetaxel following 4 cycles of PVn did not improve the overall response rate and results.

show abstract

“…Other common grade III/IV toxicities included thrombocytopenia, anemia, and nausea/vomiting, all with less than a 7% incidence of grade III/IV events. When docetaxel was combined with other drugs every 2 weeks, toxicity profile changed accordingly (Table 4) [22,[29][30][31][32][33][34][35]. Vinorelbine-containing and irinotecan-containing regimens had more myelosuppressive and gastrointestinal toxicity, respectively (Table 4).…”

Section: Discussionmentioning

confidence: 98%

Biweekly docetaxel-containing chemotherapy may be the optimal schedule

et al. 2008

View full text Add to dashboard Cite

The dosing schedule of docetaxel may affect its clinical activity and toxicity profile. Although triweekly docetaxel has higher antitumor activity but more severe hematological toxicity, weekly docetaxel seems to have less activity or fewer adverse events. To evaluate the efficacy and toxicity of biweekly docetaxel and mitoxantrone in patients with advanced breast cancer, the regimen consisting of docetaxel (60 mg/m), and mitoxantrone (8 mg/m) was administered intravenously to 59 patients every 2 weeks. Most (54.2%) of the patients experienced objective responses. The median time to progression for the whole group was 6.8 months. The median time to progression for patients with complete or partial response was 10.3 months, but only 3.6 months for patients with stable or progressive disease (P<0.001). Grade III/IV adverse events of neutropenia, thrombocytopenia, anemia, febrile neutropenia, and nausea/vomiting were documented in 61.0, 6.8, 3.4, 3.4, and 3.4% of the patients, respectively. The median overall survival was 16.9 months. In conclusion, biweekly use of docetaxel and mitoxantrone is a highly effective and well-tolerated regimen for patients with advanced breast cancer. The optimal dosage of docetaxel in combination with chemotherapeutic regimen may be given every 2 weeks.

show abstract

Biweekly Docetaxel and Vinorelbine as First-Line Chemotherapy in Metastatic Breast Cancer

Cited by 15 publications

References 15 publications

Treatment of Metastatic Breast Cancer With Vinorelbine and Docetaxel

Treatment of Metastatic Breast Cancer With Vinorelbine and Docetaxel

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

Biweekly docetaxel-containing chemotherapy may be the optimal schedule

Contact Info

Product

Resources

About